Who List Of Priority Medical Devices For Cancer Management

This is the model list and clearing house of appropriate, basic, and priority medical devices based on the list of clinical interventions selected from clinical guidelines on prevention, screening, diagnosis, treatment, palliative care, monitoring, and end of life care. This publication addresses medical devices that can be used for the management of cancer and specifically describes medical devices for six types of cancer: breast, cervical, colorectal, leukemia, lung, and prostate. This book is intended for ministries of health, public health planners, health technology managers, disease management, researchers, policy makers, funding, and procurement agencies and support and advocacy groups for cancer patients.

Background papers 1 to 9 published as technical documents. Available in separate records from WHO/HSS/EHT/DIM/10.1 to WHO/HSS/EHT/DIM/10.9

The final goal of this publication is to guide on the selection of medical devices. This increases access to medical devices required to prevent, diagnose and treat cardiovascular diseases (including stroke) and diabetes, especially in low and middle resource settings. This publication is intended for Ministries of Health, public health planners, health technology managers, disease managers, researchers, policy-makers, funding and procurement agencies, and support and advocacy groups for patients suffering from cardiac diseases, stroke and diabetes. It serves to inform policy-makers and technical decision-makers on the selection of medical devices required for the package of benefits and interventions for a target population in the context of universal health coverage.

The objective of the list is to help countries develop or update their national essential diagnostics lists, raise awareness and political will, guide procurement and regulation policies and improve access to the most important in vitro diagnostics that all countries need to make available to their populations, particularly in low-resourced countries. It will also contribute towards health systems strengthening and realizing universal health coverage.

Rare diseases collectively affect millions of Americans of all ages, but developing drugs and medical devices to prevent, diagnose, and treat these conditions is challenging. The Institute of Medicine (IOM) recommends implementing an integrated national strategy to promote rare diseases research and product development.

This publication addresses the role of the biomedical engineer in the development, regulation, management, training, and use of medical devices. The first part of the book looks at the biomedical engineering profession globally as part of the health workforce: global numbers and statistics, professional classification, general education and training, professional associations, and the certification process. The second part addresses all of the different roles that the biomedical engineer can have in the life cycle of the technology, from research and development, and innovation, mainly undertaken in academia; the regulation of devices entering the market; and the assessment or evaluation in selecting and prioritizing medical devices (usually at national level); to the role they play in the management of devices from selection and procurement to safe use in healthcare facilities. The annexes present comprehensive information on academic programs, professional societies, and relevant WHO and UN documents related to human resources for health as well as the reclassification proposal for ILO. This publication can be used to encourage the availability, recognition, and increased participation of biomedical engineers as part of the health workforce, particularly following the recent adoption of the recommendations of the UN High-Level Commission on Health Employment and Economic Growth, the WHO Global Strategy on Human Resources for Health, and the establishment of national health workforce accounts. The document also supports the aim of reclassification of the role of the biomedical engineer as a specific engineer that supports the development, access, and use of medical devices within the national, regional, and global occupation classification system.

Clinical research presents health care providers with information on the natural history and clinical presentations of disease as well as diagnostic and treatment options. In today's healthcare system, patients, physicians, clinicians and family caregivers often lack the sufficient scientific data and evidence they need to determine the best course of treatment for the patients' medical conditions. Initial National Priorities for Comparative Effectiveness Research(CER) is designed to fill this knowledge gap by assisting patients and healthcare providers across diverse settings in making more informed decisions. In this 2009 report, the Institute of Medicine's Committee on Comparative Effectiveness Research Prioritization establishes a working definition of CER, develops a priority list of research topics, and identifies the necessary requirements to support a robust and sustainable CER enterprise. As part of the 2009 American Recovery and Reinvestment Act, Congress appropriated $1.1 billion in federal support of CER, reflecting legislators' belief that better decisions about the use of health care could improve the public's health and reduce the cost of care. The Committee on Comparative Effectiveness Research Prioritization was successful in preparing a list 100 top priority CER topics and 10 recommendations for best practices in the field.

This issue of Clinics in Laboratory Medicine, edited by Dr. Dan Milner, will focus on Global Health and Pathology. Topics include, but are not limited to: Clinical Laboratory Volunteerism, Pathologists Overseas; Anatomic Pathology Volunteerism; Funding Strategies in Research and Global Pathology; Diagnostics for Cancer and Health Systems building through pathology laboratories; Training the next pathologists in global health; Maximizing internet resources for improving pathology/lab medicine in LMICs; Pathology-based research in Africa; HIV and Cancer: Role of Pathology in success; Lymphoma and Pathology in Africa: Current approaches and future diagnostics; Laboratory Capacity as a tool for building health systems; Building Cross Country Networks for Laboratory Capacity and improvement; Lab accreditation; Practical success in Telepathology experiences in Africa; Pathology and WHO vision of the future of LMICs; Breast Cancer in LMICs: Why we need pathology and clinical trial capability to solve this challenge; Cytopathology in LMICs: why and how to integrate to capacitate healthcare; and Biorepositories and Data Cores for Research in Global Health.